Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

The luxury group's jewelry division, which houses heavyweight brands Cartier and Van Cleef & Arpels, saw an 11% rise in sales. The Jeep parent said it would discontinue its hydrogen fuel-cell ...

Renault slashed its financial targets for the year, citing a worsening automotive market as the group faces stiff competition from rivals, and elevated finance chief Duncan Minto to interim CEO. J.B.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Prescriptions are required. There are several name brands available, including Ozempic, Wegovy, Zepbound and Mounjaro, as well as generics. Eligibility Criteria: Bariatric Surgery vs. GLP-1s Bariatric ...

Beyond Mounjaro and Zepbound, Lilly’s broader portfolio — including the oncology drug Verzenio and immunology drug Taltz — also continues to deliver steady growth.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.